These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16429835)

  • 1. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Clin Nephrol; 2006 Jan; 65(1):1-6. PubMed ID: 16429835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(3):175-9. PubMed ID: 10878397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome.
    Sakurai M; Muso E; Matushima H; Ono T; Sasayama S
    Kidney Int Suppl; 1999 Jul; 71():S210-2. PubMed ID: 10412778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group.
    Muso E; Mune M; Fujii Y; Imai E; Ueda N; Hatta K; Imada A; Miki S; Kuwahara T; Takamitsu Y; Takemura T; Tsubakihara Y
    Kidney Int Suppl; 1999 Jul; 71():S122-5. PubMed ID: 10412754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.
    Nakamura T; Sugaya T; Node K; Ueda Y; Koide H
    Am J Kidney Dis; 2006 Mar; 47(3):439-44. PubMed ID: 16490622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients.
    Shah L; Hooper DK; Okamura D; Wallace D; Moodalbail D; Gluck C; Koziell A; Zaritsky JJ
    Pediatr Nephrol; 2019 Nov; 34(11):2343-2350. PubMed ID: 31250206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Am J Med Sci; 2005 Oct; 330(4):161-5. PubMed ID: 16234607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Excellent antiproteinuric effect by LDL apheresis in a case with severe renal dysfunction due to focal segmental glomerulosclerosis].
    Iwahori T; Yoshida M; Sugiura M; Ioya N; Kawaguchi M
    Nihon Jinzo Gakkai Shi; 1996 Feb; 38(2):91-7. PubMed ID: 8717311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
    Tojo K; Sakai S; Miyahara T
    Prog Clin Biol Res; 1990; 337():193-4. PubMed ID: 2191313
    [No Abstract]   [Full Text] [Related]  

  • 11. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
    Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
    Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis?
    Muso E; Yashiro M; Matsushima M; Yoshida H; Sawanishi K; Sasayama S
    Nephrol Dial Transplant; 1994; 9(3):257-64. PubMed ID: 8052431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
    Tojo K; Sakai S; Miyahara T
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1153-60. PubMed ID: 3216557
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis.
    Kawasaki Y; Suzuki S; Matsumoto A; Takano K; Suyama K; Hashimoto K; Suzuki J; Suzuki H; Hosoya M
    Pediatr Nephrol; 2007 Jun; 22(6):889-92. PubMed ID: 17277952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy.
    Yokoyama K; Sakai S; Sigematsu T; Takemoto F; Hara S; Yamada A; Kawaguchi Y; Hosoya T
    Clin Nephrol; 1998 Jul; 50(1):1-7. PubMed ID: 9710340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposorber® LA-15 system for LDL apheresis in resistant nephrotic syndrome patients.
    Al-Mousily M; Nicoara O; Selewski DT; Twombley K
    Pediatr Nephrol; 2022 Mar; 37(3):585-592. PubMed ID: 34453196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of noninvasive methods for distinguishing steroid-sensitive nephrotic syndrome from focal glomerulosclerosis.
    Ramjee G; Coovadia HM; Adhikari M
    J Lab Clin Med; 1997 Jan; 129(1):47-52. PubMed ID: 9011590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease.
    Fukuda Y; Miura S; Zhang B; Iwata A; Kawamura A; Nishikawa H; Shirai K; Saku K
    Intern Med; 2009; 48(19):1731-7. PubMed ID: 19797828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.
    Nakamura T; Sugaya T; Ebihara I; Koide H
    Am J Nephrol; 2005; 25(5):447-50. PubMed ID: 16118482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis.
    Bazzi C; Petrini C; Rizza V; Arrigo G; Napodano P; Paparella M; D'Amico G
    Nephrol Dial Transplant; 2002 Nov; 17(11):1890-6. PubMed ID: 12401843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.